Dactolisib is an imidazoquinoline compound that functions as a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR. It has been investigated as an antineoplastic agent in cancer research.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 915019-65-7
Flurbiprofen axetil
pharmaceutical raw material
(R)-4-((3R,5S,6R,8S,9S,10S,13R,14S,17R)-6-ethyl-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
pharmaceutical raw material
Enzalutamide
pharmaceutical raw material
Telmisartan amide
pharmaceutical raw material
2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile
JOGKUKXHTYWRGZ-UHFFFAOYSA-N
CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5